Olamkicept
Modify Date: 2024-01-02 02:10:57
Olamkicept structure
|
Common Name | Olamkicept | ||
|---|---|---|---|---|
| CAS Number | 1702282-14-1 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of OlamkiceptOlamkicept (FE 999301) is a selective inhibitor of the soluble interleukin 6 (sIL-6R)/IL-6 complex. Olamkicept is a soluble gp130-Fc-fusion-protein and anti-inflammatory agent[1][2]. |
| Name | Olamkicept |
|---|
| Description | Olamkicept (FE 999301) is a selective inhibitor of the soluble interleukin 6 (sIL-6R)/IL-6 complex. Olamkicept is a soluble gp130-Fc-fusion-protein and anti-inflammatory agent[1][2]. |
|---|---|
| Related Catalog | |
| Target |
sIL-6R/IL-6 Complex[1] |
| In Vitro | Olamkicept (10 µg/mL，60 分钟) 抑制 HREC 中 IL-6 转信号介导的 STAT3 激活[5]。 Olamkicept (10 µg/mL，60 分钟) 抑制 IL-6 转导信号诱导的 HREC 中 H2O2 水平的增加[5]. Olamkicept (10 µg/mL，60 分钟) 抑制 IL-6 转导诱导的 HREC 细胞凋亡[5]。 Olamkicept (0-1 µg/mL) 抑制 IL-11/重组 sIL-11R 诱导的 Ba/F3-gp130 细胞增殖[6]。 Western Blot Analysis[5] Cell Line: Human retinal endothelial cells (HRECs) Concentration: 10 µg/mL Incubation Time: 60 min Result: Inhibited IL-6/sIL-6R induced increase in STAT3 phosphorylation. |
| In Vivo | Olamkicept (sgp130Fc) (0.01-10 mg/kg，皮下注射) 提高盲肠结扎穿孔 (CLP) 败血症小鼠模型的存活率[3]。 Olamkicept (0.5 mg/kg，腹腔注射) 抑制盲肠结扎穿孔 (CLP) 诱导的败血症小鼠的炎症并提高存活率[4]。 Animal Model: Cecal ligation and puncture (CLP) sepsis mice model[3] Dosage: 0.01, 0.1, 1, 10 mg/kg Administration: s.c. Result: Improved survival rate and physical activity. |
| References |
| No Any Chemical & Physical Properties |